Journal of Hebei Medical University

Previous Articles     Next Articles

  

  1. 1.Department of Internal Medicine, the Second Hospital of Anhui Medical University, Hefei 230601, China;
    2.Department of Internal Medicine, the PLA Navy Anqing Hospital, Anhui Province, Anqing 246003, China
  • Online:2017-04-25 Published:2017-04-25

Abstract: [Abstract]  Objective〖HTSS〗〓To observe the effect of simvastatin on plasma tissue factor and tissue factor pathway inhibitor in hemodialysis patients,and to explore the value of simvastatin in the treatment of hemodialysis patients.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓Ninety cases of chronic renal failure patients with hemodialysis treatment were randomly divided into conventional treatment group and simvastatin treatment group, and 50 cases healthy people received in the same period as control group. Plasma tissue factor(TF), tissue factor pathway inhibitor(TFPI) activity and blood lipid level triglyceride(TG), total cholesterol(TC), high density lipoprotein cholesterol(HDLC) and low density lipoprotein cholesterol(LDLC) changes before and after treatment were compared.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓TF and TFPI activity in chronic renal failure patients were significantly higher than those in control group(P<005) . TF levels after treatment in two groups were significant lower than before, and TFPI levels were significant higher than before,but TF and TFPI activity in simvastatin treatment group was significantly lower than conventional treatment group(P<005). TG, TC and LDLC in two groups after treatment were significantly lower than before, HDLC was higher than before,TG, TC and LDLC in the simvastatin treatment group were significantly lower than those in conventional treatment group, and the HDLC was significantly higher than that in conventional treatment group(P<005), there was no significant difference in the incidence of adverse reactions between the two groups(P>005). Pearson correlation analysis showed that TF and TPPI levels were not correlated with TG, TC, HDLC and LDLC(P>005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓20 mg simvastatin treatment in maintenance hemodialysis patients can reduce the tissue factor activity, increase tissue factor pathway inhibitor level, which was important for correcting coagulation disorders in hemodialysis patients.

Key words: renal insufficiency; renal dialysis; simvastatin, thromboplastin